← All trials
NCT06429475
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2024
- Primary completion
- May 28, 2025
- Completion date
- May 28, 2026
- First posted
- May 28, 2024
- Last posted
- May 28, 2024
- Enrollment
- 1038
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Kwa-Zulu NatalLead sponsor
- Africa Health Research InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.